EU, U.K. Signal Vaccine Progress

The transcript discusses the slight differences in vaccine efficacy rates and the actions of the DSMB, which are seen as minor yet have caused significant public and PR challenges for AstraZeneca. Despite these issues, the FDA's focus remains on data, not public perception. The conversation also touches on the EU-UK vaccine export situation, emphasizing the need for political restraint to allow scientific progress.

What did the speaker suggest about the impact of the trial data on AstraZeneca's approval in the United States?

What was the speaker's wish regarding the involvement of politicians in the vaccine rollout?